NEXOBRIEF
Your daily cheat code on finance, AI, current events & startups
Friday, April 24, 2026 | Issue #030 | 5 min read | No MBA Required
Good morning. The ceasefire got extended — again. A pancreatic cancer drug just hit phase 3 with stunning results. The universe is expanding faster than physics can explain. Melatonin may be quietly wrecking your long-term health. And a startup founded by Neuralink's co-founder is about to become the first brain implant company with an actual product on the market. Let's go.
⚡ BIG STORY
The Ceasefire Got Extended. The Blockade Stays. The War Is in a Holding Pattern.
Just before the ceasefire was set to expire Tuesday night, it was extended — again. The extension buys more time for talks that haven't produced a deal. The U.S. naval blockade of Iranian ports remains in place. Iran's position hasn't shifted: the blockade is an act of war and any ceasefire that doesn't include lifting it is meaningless. The U.S. position hasn't shifted either: the blockade is leverage, and leverage doesn't get surrendered before a deal.
In the meantime, three ships were attacked in the Strait of Hormuz on Wednesday — the day after the extension. A U.S. Navy vessel fired on an Iranian-flagged ship the previous week after it attempted to breach the blockade. The ceasefire is a name for something that isn't really a ceasefire. Both sides know it.
The global economic read:
The IMF's April 2026 World Economic Outlook projects global growth at just 3.1% — below recent outcomes and well under pre-pandemic averages. Oil assumed at $82 per barrel for 2026. The war is the primary downside risk cited
Global inflation is expected to tick up in 2026 before declining in 2027 — assuming the conflict stays limited. If it doesn't, the scenarios are significantly worse
Emerging markets are absorbing the most pain — commodity importers with pre-existing debt vulnerabilities are getting hit hardest by elevated energy and food costs
NexoBrief take: The ceasefire extension is better than no ceasefire. It is not a peace process. Every extension without a framework makes the next negotiation harder. At some point the extensions run out.
💰 MONEY MINUTE
A Pancreatic Cancer Drug Just Posted the Best Phase 3 Data in the Field's History.
Revolution Medicines dropped phase 3 data this week for daraxonrasib — a drug targeting the KRAS mutation found in 90% of pancreatic cancers, one of the most lethal and treatment-resistant cancers in medicine. The results were headline-grabbing: significant improvement in overall survival in patients with previously untreatable KRAS-mutated pancreatic cancer. This is the mutation that has resisted drug targeting for 40 years.
Pancreatic cancer has a 5-year survival rate of around 12% — one of the lowest of any cancer. It's typically diagnosed late, spreads fast, and has been essentially impervious to targeted therapy. Daraxonrasib doesn't cure it. But meaningful survival improvement in a disease this hard to treat is extraordinary.
The investment angle:
Revolution Medicines' stock surged on the data — and dragged biotech peers up with it. Any credible KRAS inhibitor validates the entire class of drugs
Merck separately announced a $1 billion investment in Google Cloud this week for AI-driven drug discovery — the pharma-AI integration is accelerating on multiple fronts simultaneously
The psychedelics EO signed last weekend and the KRAS breakthrough represent two separate but converging waves of medical innovation: one policy-driven, one science-driven. Both arriving at once
NexoBrief take: KRAS has been called the 'undruggable' target for four decades. Revolution Medicines just drugged it. If the FDA approves daraxonrasib, it becomes one of the most significant oncology advances in years. Watch the NDA filing timeline.
🤖 AI TOOL OF THE DAY
The Universe Is Expanding Faster Than Physics Says It Should. AI Found the Discrepancy.
The most precise measurement ever taken of the Hubble constant — the rate at which the universe is expanding — was published this week, and the number doesn't match what our best physical models predict. The universe is expanding roughly 8% faster than the standard model of cosmology says it should. This discrepancy, known as the Hubble tension, has been debated for years. This measurement makes it harder to explain away.
The measurement was made using AI-assisted analysis of gravitational lensing data — light from distant quasars bent by galaxy clusters between them and Earth. AI models identified patterns in the lensing that would have taken years of manual analysis to extract. The result is the most statistically significant challenge yet to the standard cosmological model.
Why this matters:
If the universe is genuinely expanding faster than predicted, something is wrong with our understanding of dark energy, dark matter, or the fundamental physics of the early universe — or all three
AI-assisted cosmological analysis is becoming the primary tool for these measurements — not just automating existing work but enabling precision that wasn't achievable before
The finding also reinforces a broader pattern: some of the most significant scientific discoveries of 2026 are AI-assisted revelations of gaps in what we thought we knew
NexoBrief take: The universe refusing to behave according to our best models is the most interesting problem in physics right now. The fact that AI is what's sharpening the discrepancy — making it harder to explain away — is the science story of the year.
🚀 STARTUP SPOTLIGHT
Science Corp Is About to Beat Neuralink to Market. The Brain Implant Race Has a New Leader.
Science Corporation — founded by Max Hodak, the co-founder and former president of Neuralink — just closed a $230 million Series C at a $1.5 billion valuation. The company's flagship product is PRIMA: a chip smaller than a grain of rice that implants in the eye and works with camera-equipped glasses to restore functional vision to patients with advanced macular degeneration.
Science Corp has submitted its CE mark application to the European Union and expects approval in mid-2026 — which would make it the first brain-computer interface company with an actual product in market. Anywhere. Before Neuralink. Before Synchron. Before everyone.
What makes this company different:
PRIMA targets macular degeneration — the leading cause of vision loss in adults over 60, affecting 200 million people globally. It's a massive, well-defined patient population with no current cure
Science Corp owns its own chip manufacturing through its Science Foundry division — acquired MEMS fabrication assets in North Carolina, giving it in-house production that competitors outsource
A second business line, Vessel, is building miniaturized organ preservation technology that could allow organs to be transported on commercial flights rather than in ICU suites — an entirely separate multi-billion dollar market
Investors include Lightspeed, Khosla Ventures, Y Combinator, and IQT — the nonprofit investment firm that works with the FBI and CIA. That last backer is a signal about what governments think this technology could eventually do.
NexoBrief take: The brain-computer interface race has been dominated by Neuralink's narrative for years. Science Corp is about to put a product in European patients' eyes before Neuralink has its first approved commercial device. The race has a new frontrunner.
🌍 CURRENT EVENTS
Melatonin May Be Hurting You. Alzheimer's Starts in the Body. And a 2,500-Year-Old Helmet Came Home.
Melatonin's long-term risks are being flagged:
A common sleep supplement may carry unexpected risks when used long-term, according to research published this week. Melatonin has long been considered safe and non-habit-forming — but new evidence suggests chronic use may interfere with the body's natural hormone regulation, affect reproductive health, and in some cases disrupt rather than improve sleep architecture over time. The supplement market for melatonin is $900 million annually in the U.S. alone. The research doesn't say stop taking it. It says the long-term picture is more complicated than the label suggests.
Alzheimer's may start in the peripheral nervous system:
New research from April 22 found that certain movement-related symptoms of Alzheimer's disease may originate outside the brain — in the peripheral nervous system, specifically in nerve cells in the gut and limbs. This challenges the brain-centric model of Alzheimer's progression and could open entirely new treatment targets. If Alzheimer's begins in the body before it reaches the brain, there's a window to intervene before cognitive damage begins.
Three more quick:
A 2,500-year-old Dacian gold helmet stolen from a Dutch museum in January 2025 was recovered by Dutch authorities and returned to Romania this week — presented at a press conference at the National Museum of Romanian History. It had been missing for 15 months
Cancer cells may 'learn' to survive chemotherapy by rewiring gene activity using AP-1 proteins — a newly identified mechanism that helps tumors develop drug resistance. Blocking AP-1 could prevent that adaptation
Australia is in the middle of a fuel crisis — and both state and federal governments responded by committing billions to fossil fuel infrastructure, signaling that the green transition is moving slower on the ground than in the headlines
NexoBrief take: The Alzheimer's peripheral nervous system finding is the one to sit with. If we've been looking in the wrong place — treating the brain when the disease starts in the body — that changes the entire research and treatment paradigm. Early days, but worth watching closely.
NEXOBRIEF
nexobrief.com | Free. Every weekday at 7am.
Finance, AI, Current Events, Startups — No MBA Required.
Have a great weekend. See you Monday.